Background: Gliomas are highly malignant brain tumors. Aberrant activation of NF-κB plays a crucial role in tumor progression. Method: ELISA assay was used to detect NF-κB activity in glimoas cells with different treatments. PPP3CC expression was evaluated by qRT-PCR and western blot assay. Kaplan-Meier analysis estimated the overall survival rates according to the protein level of PPP3CC. Transwell and MTS assay were performed to determine cell invasion and growth. Chromatin immunoprecipitation combined with luciferase reporter assays illustrated the transcriptional regulation of PPP3CC. Results: We showed that PPP3CC decrease was responsible for constitutive activation of NF-κB in gliomas. Restored PPP3CC expression inhibited activation of NF-κB. PPP3CC was frequently decreased in gliomas and that repression of the expression of PPP3CC correlated glioma progression. The ectopic expression of PPP3CC inhibited the invasive potential of glioma cells, and inhibited glioma cells proliferation in vitro and growth in vivo. Additionally, the expression of Zinc finger E-box-binding homeobox 1(ZEB1) was increased in gliomas and was negatively correlated with clinical outcomes of glioma patients. ZEB1 inversely correlated with the expression of PPP3CC. ZEB1 was also confirmed to physically bind to the PPP3CC promoter. ZEB1 knockdown resulted in an increase in the expression of PPP3CC and elevation of PPP3CC promoter activity in glioma cells. Conclusion: These findings indicated that the down-regulation of PPP3CC by ZEB1 resulted in activation of NF-κB is a critical oncogenic event in gliomas.
Introduction
Glioma is the most common type of primary brain tumors in adults. Glioma accounts for the great majority of primary tumors in adult central nervous system and is characterized by mortality rate (1) .
Gliomas are divided into several histological subtypes, including astrocytomas, ependymomas and oligodendrogliomas. Gliomas are histologically classified into four malignancy grades (I-IV), according to the World Health Organization grading criteria (2) . Despite advancements in both diagnostic modalities and therapeutic strategies over the past several decades, the prognosis of glioma patients remains dismal, with the lowest 5 year survival rate among all the human cancer types. High-grade gliomas (WHO Grade III-IV) are malignant and carry a worse prognosis, because of their rapid progression and resistance to conventional therapy (3) .
The NF-κB transcription factors play an essential role in the regulation of many biological processes, such as innate and adaptive immune responses, inflammation, cell proliferation and apoptosis (4) . Aberrant activation of NF-κB has been recognized as a crucial molecular event in cancer initiation and progression (5) . The NF-κB family is composed of five members RelA(p65), NF-κB1 (p50/p100), RelB, c-Rel, NF-κB2 (p52/p105). The NF-κB family members share a Rel homology domain (RHD) that mediates their dimerization and DNA binding (6) . Without stimuli, NF-κB dimers remain inactive in the cytoplasm, resulting from their interaction with the inhibitory proteins of IκB family that leads to NF-κB transcriptional inactivation (6) . There are two pathways mediating NF-κB activation. The classical NF-κB activation pathway is usually triggered in response to pro-inflammatory cytokines and exposure to genotoxic stress that activate the tripartite IKK complex, leading to the phosphorylation and degradation of IκBs. Subsequently, NF-κB dimers, mainly p50:p65 are released and translocate to the nucleus and regulate the expression of NF-κB target genes involved in many biological processes. This pathway mainly depends on the IKKβ function (7) . The alternative pathway leads to selective activation of p52:RelB NF-κB dimers by inducing the process of NF-κB2/p100 precursor that binds to the RelB in the cytoplasm (7) . Increased or constitutive NF-κB activation has been reported in various types of human malignancy. However, how NF-κB as inflammatory signaling is constitutively activated and maintained in cancer cells and its difference from normal immune responses are largely unknown (8, 9) . Because of the important roles of NF-κB signaling in tumorgenesis, progression and metastasis, it has been recognized as one of the most important targets in cancer treatment (10) . However, the application of IKK/NF-κB inhibitors for the treatment of human cancer is impeded by the severe side effects related to immunosuppression, because of the indiscriminate inhibition of IKK/NF-κB signaling in normal immune cells. Thus, to explore IKK-independent mechanisms for NF-κB activation selectively in cancer cells, and strategies that specifically target NF-κB activity only in cancer cells while sparing the NF-κB immune response in normal cells would be highly desirable.
NF-κB activity in gliomas is markedly higher than that in normal brain tissues. The mechanisms for constitutive NF-κB activation also remain elusive. Here, our findings indicated that ZEB1 mediated PPP3CC decrease leads to phosphorylation of IκBα and then contributes the constitutive NF-κB activation in glioma cells.
Materials and methods

Cell culture, transfection and clinical specimens
The A-172, U-87MG, U-118MG, SW1088 and T98G human glioma cell lines were obtained from American Type Culture Collection (Manassas, VA, USA) and maintained at 37°C in a humidified atmosphere containing 5% CO 2 . The cells were cultured in DMEM supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). For PPP3CC overexpression, PPP3CC and ZEB1 knockdown, the cells were transfected with the PPP3CC-overexpressing vector pcDNA3.1-PPP3CC, or with the pSUPER vector containing PPP3CC-or ZEB1-specific short hairpin (sh) RNAs, respectively (Guangzhou Fulengen Co., Ltd., Guangzhou, China). Transfection was performed using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in accordance with the manufacturer's protocol. A total of 17 paired fresh glioma tissues and adjacent non-tumor tissues were collected between January 2014 and September 2015, and 60 formalin-fixed paraffin-embedded glioma tissues were collected between June 2007 and October 2010, at Xiangyang Central Hospital (Hubei, China). The fresh tissue samples were immediately snap-frozen in liquid nitrogen and were used for RNA extraction. Each of the patients provided written informed consent and the present study was approved by ethics committee of Xiangyang Central Hospital. In some experiments, related cells were treated with Cantharidin (0.5 μM), Endothall (1 μM), RK-682 (10 μM), RWJ-60475 (2 μM), Cypermethrin (1 μM), Deltamethrin (1 μM), Fenvalerate (0.1 μM), Tyrphostin 8 (10 μM), CinnGel (1 μM), NSC-95397 (0.1 μM), BN-82002 (5 μM), Shikonin (1 μM), Cyclosporin A (1 μM), Pentamidine (10 μM), BVT-948 (1 μM), BML-260 (10 μM), OBA (10 μM) and Alendronate (1 μM). The inhibitors were from Calbiochem (Merck KGaA, Darmstadt, Germany) or Enzo Life Science (New York, NY, USA).
NF-κB activity assay
NF-κB activity was examined using the ELISA-based TransAMNF-κB Family kit (Active Motif, Carlsbad, CA, USA) according to manufacturer's instructions. The oligonucleotides containing the NF-κB consensus site (5′-GGGACTTTCC-3′) is coated on a plate to capture the active form of NF-κB contained in the nuclear extract of analyzed cells. Primary antibodies against active forms of p65, together with an HRP-conjugated secondary antibody are used to detect a colorimetric readout at 450 nm which is normalized to the reference wavelength of 655 nm. Nuclear extracts were prepared using NE-PER Nuclear Extract kit (Thermo Fisher Scientific) and assayed in triplicates and repeated for three times. The data are presented as mean ± SD.
Western blot analysis
Total proteins were extracted from the corresponding cells using RIPA buffer (Thermo Fisher Scientific, Inc.) in the presence of a protease inhibitor cocktail (Thermo Fisher Scientific, Inc.). The protein concentrations of the lysates were measured using a BCA Protein Assay kit (Thermo Fisher Scientific, Inc.). 50 μg protein was resolved and mixed with 5×Lane Marker Reducing Sample Buffer (Thermo Fisher Scientific, Inc.), electrophoresed on a 10% SDS-acrylamide gel and transferred onto an Immobilon-P Transfer Membrane (Merck KGaA, Darmstadt, Germany). The membranes were blocked with 5% non-fat milk in Tris-buffered saline, following which they were incubated with primary antibodies at 4°C overnight, followed by a secondary antibody at room temperature for 2 h. The signal was detected using an ECL detection system (Merck KGaA). The p-IκBα antibody (#9246; 1:1000), IκBα antibody (#4812; 1000), ZEB1 antibody (#3396; 1:1000) and β-Actin antibody (#8457; 1:2000) were obtained from Cell Signaling Technology (Danvers, MA, USA). The PPP3CC antibody was from Abcam (Cambridge, MA, USA). The horseradish peroxidase-conjugated secondary antibody (#31460; 1:20 000) was from Thermo Fisher Scientific, Inc.
qRT-PCR analysis
Tissues were excised and homogenized under liquid nitrogen. Total RNA from the cells and tumor tissues were extracted using TRIzol reagent, and 2 μg mRNAs was used to synthesize cDNAs using the Super-Script first-strand synthesis system (Thermo Fisher Scientific, Inc.). 1 μl cDNAs was used for qRT-PCR and the qRT-PCR analysis was performed according to the standard protocol of the ABI 7500 system with SYBR Green supermix (Applied Biosystems; Thermo Fisher Scientific, Inc.). The reaction system (20 μl) included 1 μl cDNA, 2 μl primer mix, 10 μl SYBR green PCR Master Mix and 7 μl ddH 2 O (Thermo Fisher Scientific, Inc.). GAPDH was used as an internal control and the qRT-PCR analysis was repeated biologically three times with four technique repeats for each. The primers were listed as follows: GAPDH, forward 5′-CTCCTGTTCGACAGTCA GCC-3′ and reverse 5′-GCCCAATACGACCAAATCCG-3′; PPP3CC, forward 5′-AAGGAAGGACGACTGGAAGAG-3′ and reverse 5′-CG TGTGTTACTAGGTGATCCTCC-3′; ZEB1, forward 5′-GATGATGAA TGCGAGTCAGATGC-3′ and reverse 5′-ACAGCAGTGTCTTGTT GTTGT-3′. The PCR conditions were as follows: one cycle at 95°C for 5 min; 40 cycles at 95°C for 45 s, 61°C for 30 s and 72°C for 30 s; and one cycle at 72°C for 10 min. Cycle threshold values were established, and data were analyzed using 2 −ΔΔCq method.
Immunohistochemistry
The tissue specimens were cut into 4-μm sections and the sections dried at 55°C for 2 h, deparaffinized in xylene and rehydrated using a series of graded alcohol washes. The tissue slides were then treated with 3% hydrogen peroxide in methanol for 15 min to quench endogenous peroxidase activity, following which antigen retrieval was performed by incubation at 98-100°C for 10 min in 0.01 M sodium citrate buffer (pH 6.0), heated using a microwave oven. Following preincubation for 1 h in 10% goat serum (Gibco; Thermo Fisher Scientific, Inc.), the specimens were incubated with the p-IκBα (1:150) antibody, PPP3CC antibody (1:200) and ZEB1 antibody (1:200) for 1 h at room temperature. The tissue slides were treated with a non-biotin horseradish peroxidase detection system according to the manufacturer's protocol (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA). The images were obtained using a light microscope (LEICA DM6000; Leica Microsystems GmbH, Wetzlar, Germany). Two pathologists evaluated the immunohistological samples and the intensity of immunostaining was considered when analyzing the data. The intensity of staining was scored (0-3) and the expression was classified as high if the score was ≥2, and low if the score was ≤1.
Cell invasion assay
Invasion of the cells was assessed using a Cell Invasion Assay kit (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's protocol. Briefly, at 36 h post-transfection, 3 × 10 4 cells in 300 μl serum-free medium were added to the upper chamber precoated with ECMatrix™ gel. Subsequently, 0.5 ml of 10% FBS-containing medium was added to the lower chamber as a chemoattractant. The cells were incubated for 24 h at 37°C, following which the non-invading cells were removed with cotton swabs. The cells, which had migrated to the bottom of the membrane were fixed with pre-cooled methanol and stained with 2% Giemsa solution. The stained cells were visualized under a light microscope. To minimize bias, at least three randomly selected fields (magnification, ×100) were counted, and the average number was determined.
Cell proliferation assay
Cell proliferation was monitored using an MTS assay with the CellTiter96 ® AQueous One Solution Cell Proliferation Assay kit (Promega Corporation, Madison, WI, USA) according to the manufacturer's protocol. The cells were seeded into 96-well plates at 2 000 cells/well (0.20 ml/well). The cell proliferation assay was performed on Day 1, 3 and 5 by incubation with MTS (0.02 ml/well) at 37°C for 3 h. The absorbance at 490 nm was recorded for each well on the BioTek Synergy 2 reader (BioTek Instruments, Inc., Winooski, VT, USA). The absorbance represented the cell number, with the absorbance of the control set as 100%.
Xenograft model in nude mice
Xenograft tumors were generated by subcutaneous injection of PPP3CC overexpressed U-118MG cell lines and its control cell line at 1 × 10 6 cells in 200 μl, respectively, into the hind limbs of 4-6 week-old female Balb/C athymic nude mice, with three mice for each cell line. All mice were housed and maintained under specific pathogen-free conditions at 27°C with 12:12 h light:dark cycle and fed with sterilized food and water, and all animal experiments were approved by the Experimental Animal Ethics Committee of Hubei University of Medicine and performed in accordance with institutional guidelines. Tumor growth was examined every 3 days during the animal experiment. The mice were sacrificed with 120 μl 10% hydral (Sinopharm Chemical Reagent Co., Ltd, Shanghai, China) 27 days later and the tumors were harvested and weighed.
Chromatin immunoprecipitation (ChIP) assay
Using the high-quality transcription factor binding profile database (JASPAR database; http://jaspar.binf.ku.dk), ZEB1 was predicted for regulating PPP3CC transcription. To determine whether ZEB1 could bind to the PPP3CC promoter, the ChIP assay was applied in the present study. The ChIP assay was performed using an EZ-CHIP TM chromatin immunoprecipitation kit (Merck KGaA). Briefly, chromatin proteins were cross-linked to DNA by the addition of formaldehyde to the culture medium to a final concentration of 1%. Following incubation for 10 mins at room temperature, the cells (2 × 10 5 ) were washed and scraped off in ice-cold phosphate-buffered saline containing Protease Inhibitor Cocktail II. The cells were pelleted and then resuspended in lysis buffer containing Protease Inhibitor Cocktail II. The resulting lysate was subjected to sonication to reduce the size of DNA to~200-1 000 base pairs in length. The sample was centrifuged at 10 000× g at 4°C for 10 min to remove cell debris and diluted 10-fold in ChIP dilution buffer containing Protease Inhibitor Cocktail II. A 5 μl sample of the supernatant was retained as 'Input' and stored at 4°C. Subsequently, 5 μg of anti-RNA polymerase antibody (positive control, included in the kit), anti-ZEB1 antibody (Cell Signaling Technology, Inc.) or IgG (negative control) were added to the chromatin solution and incubated overnight at 4°C with rotation. Following antibody incubation, protein G agarose was added and the sample was incubated at 4°C with rotation for an additional 2 h. The protein/DNA complexes were washed with wash buffers four times and eluted with ChIP elution buffer. Cross-links were then reversed to free DNA by the addition of 5 M NaCl and incubation at 65°C for 4 h. The DNA was purified according to the manufacturer's protocol. A total of 50 μl of DNA was obtained for each treatment, and 0.2 μl of the DNA from each group was used as a template for PCR. The total 20 μl reaction system include 0.2 μl cDNA, 2 μl primer mix, 10 μl PCR Master Mix and 7.8 μl ddH 2 O (Thermo Fisher Scientific, Inc.). The primers for the PPP3CC promoter containing putative ZEB1 binding sites were as follows: sense 5′-GGTTCCACAGTGAGCCTGG-3′ and antisense 5′-CT GAGCAAGGCTCTGCTCCC-3′. Primers for the human GAPDH gene were as follows: Sense 5′-TACTAGCGGTTTTACGGGCG-3′ and antisense 5′-TCGAACAGGAGGAGCAGAGAGCGA-3′. The PCR conditions were as follows: one cycle of 95°C for 5 min; 32 cycles of 95°C for 20 s, 59°C for 30 s, 72°C for 30 s; and one cycle of 72°C for 10 min. The PCR samples were resolved by electrophoresis on a 2% agarose gel and stained with ethidium bromide.
Promoter activity analysis
To determine whether ZEB1 regulated the promoter activity of PPP3CC, a 2 kb region upstream of transcription start site of PPP3CC was cloned into the pGL4-reporter vector upstream of the luciferase gene. The cells were seeded (1 × 10 4 /well) in 96-well plates and co-transfected with the pGL4-reporter vector or pRL-TK Renilla luciferase vector, with or without the pSUPER-sh-ZEB1
vector, using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). The transfection was performed at room temperature. After transfection, the cells were incubated at 37°C in cell culture conditions. After 48 h, luciferase activity was determined using a Dual-Luciferase Reporter Assay system (Promega Corporation) on a BioTek Synergy 2 reader (BioTek Instruments, Inc.). The activity of Renilla luciferase was used as an internal control and firefly luciferase activity was calculated as the mean ± standard deviation following normalization relative to the activity of Renilla luciferase.
Statistical analysis
All statistical analysis were performed using SPSS statistical software (version 21.0; IBM SPSS, Armonk, NY, USA). The results are reported as mean ± standard deviation. The difference between groups was analyzed using Student's t test. Pearson correlation analysis was performed to determine the correlation between two variables. Pearson's chi-square test or Fisher exact test was used to analyze the clinical variables. Survival curves were constructed using the Kaplan-Meier method and analyzed using the log-rank test. we have included patients' performance status, type and detailed treatment content, MGMT promoter methylation status and age these elements for survival benefits in Kaplan-Meier analysis. P < 0.05 was considered to indicate a statistically significant difference.
Results
PPP3CC decrease controls NF-κB activation in glioma cells
In order to explore the mechanisms of NF-κB activation in glioma cells, we firstly detected the NF-κB (p65) activity in a series of glioma cell lines. We found that NF-κB (p65) activity and phosphorylation of IκBα were increased in glioma cell lines, especially in U-118MG and SW1088 cell lines (Fig. 1A and B) . Then, a series of phosphatase inhibitors were used to screen the phosphatases which confer the constitutive IκBα phosphorylation in A-172 cells with relative low NF-κB (p65) activation. The experimental results indicated that treatment with the phosphatase inhibitors, cypermethrin and deltamethrin, increased p65 activity (Fig. 1C) and p-IκBα level (Fig. 1D) . Both cypermethrin and deltamethrin can inhibit serine/threonine-protein phosphatase 2b (PP2B). PP2B also termed as calcineurin (CN) is composed of a catalytic subunit (CNA) and a regulatory subunit (CNB). CNA includes three isoforms: CNAα (PPP3CA), CNAβ (PPP3CB) and CNAγ (PPP3CC). CNB includes two isoforms: CNBα (PPP3R1) and CNBβ (PPP3R2). We found that compared with endogenous control, PPP3CC mRNA and protein was down-regulated in glioma cells, especially in U-118 and SW1088 cell lines with relative high NF-κB activation (Fig. 1E) . Whereas, there was no significant difference in the expression of other PP2B catalytic and regulatory isoforms between glioma cell lines with different NF-κB activation (data not shown). Additionally, PPP3CC in A-172 was knocked down by transfection with shRNAs (Fig. 1F) . PPP3CC knockdown resulted in increased p-IκBα level and p65 activity, but decreased IκBα protein level (Fig. 1E) . However, stable PPP3CC overexpression by transfection with PPP3CC expressing plasmid pcDNA-PPP3CC in U-118 and SW1088 cell lines resulted in decreased p-IκBα level and p65 activity, but increased IκBα protein level in U-118MG and SW1088 cell lines (Fig. 1G) . These results suggest that PPP3CC down-regulation contributes to constitutive IκBα phosphorylation and NF-κB activation in glioma cells.
PPP3CC decrease correlates with NF-κB activation and tumor progression in glioma
To determine the role of PPP3CC in glioma, here, we detected PPP3CC expression pattern in glioma tissues. qRT-PCR analysis was used to detect PPP3CC mRNA in 17 primary glioma tissues. Compared with matched non-tumor brain tissues, PPP3CC mRNA was down-regulated in the majority of primary glioma tissues ( Fig. 2A) . Because there was no follow-up data for the primary glioma tissues used in qRT-PCR analysis, the other cohort of 67 tissues (including seven normal brain tissues and 60 glioma tissues) with follow-up data were used to confirm the protein levels of PPP3CC and p-IκBα via immunohistochemical staining. Compared with normal tissues, PPP3CC protein was down-regulated in glioma tissues (Fig. 2B) . The PPP3CC down-regulation correlated with increases of tumor size and tumor grade (Table 1) . However, p-IκBα level (indicating NF-κB activation) was up-regulated in glioma tissues and negatively correlated with PPP3CC level (Fig. 2B and C) . Of note, it was observed that lower PPP3CC protein levels in patients with glioma were predictive of poorer overall survival rate (Fig. 2D) . These results indicated that PPP3CC expression was down-regulated in gliomas and correlated with glioma progression. shown by cell counts per area. ***P < 0.001. (B) PPP3CC inhibited U-118MG and SW1088 cell proliferation, determined using an MTS assay. ***P < 0.001. (C) PPP3CC was overexpressed in U-118MG cells, and these cells were injected in nude mice. Tumor growth was monitored every 3 days. Tumor weight was recorded at the experimental endpoint. Data are presented as the mean ± standard deviation from five mice. *P < 0.05, ***P < 0.001.
PPP3CC inhibits glioma cells invasion and growth
To observe the functional role of PPP3CC in glioma, here U-118MG and SW1088 cell lines with relative low PPP3CC expression and high NF-κB activation were selected for PPP3CC overexpression. Stable PPP3CC overexpressed U-118 and SW1088 cell lines were established by transfection with PPP3CC expressing plasmid pcDNA-PPP3CC (Fig. 1G) . It is found that PPP3CC overexpression reduced marked invasion in U118MG and SW1088 cell lines (Fig. 3A) . Additionally, PPP3CC overexpression significantly inhibited growth of U-118MG and SW1088 cell lines in vitro (Fig. 3B) . The effect of PPP3CC on tumor growth in glioma was further confirmed in nude mice with human glioma xenografts. This involved subcutaneous injection into the armpit of athymic mice with PPP3CC-overexpressing U-118MG cell line and its associated control cell line. As shown, the tumor sizes derived from the PPP3CC-overexpressing U-118MG cell line were marked reduced (Fig. 3C) . These results suggested that restored PPP3CC expression inhibited cell invasion and growth in glioma cells.
ZEB1 expression is inversely correlated with PPP3CC expression
To determine whether transcriptional regulation contributed to the down-regulation of PPP3CC, the potential response elements of a cohort of transcription factors located within a 2 kb region upstream of transcription start sit of the PPP3CC gene. Using the JASPAR database, a putative ZEB1 binding site (CACCTG) was predicted within this region (Fig. 4A) , suggesting that PPP3CC expression decrease may be resulted from ZEB1 increase in glioma. As expected, in the 17 primary glioma tissue samples, compared with the matched non-tumor brain tissues, the ZEB1 mRNA was upregulated in the majority of primary glioma tissues (Fig. 4B) . The ZEB1 mRNA levels were inversely correlated with the PPP3CC mRNA levels (Fig. 4C) . The ZEB1 protein levels were also confirmed via immunohistochemical staining of the 67 tissues in which the PPP3CC protein levels were detected. Compared with normal tissues, the ZEB1 protein levels were higher in glioma tissues (Fig. 2D ) and negatively correlated with PPP3CC protein levels (Fig. 4D) . The up-regulation of ZEB1 was predictive of a poorer overall survival rate in glioma patients (Fig. 4E) . These data indicated a negative correlation between ZEB1 and PPP3CC in glioma.
ZEB1 transcriptionally represses PPP3CC expression in glioma cells
Because ZEB1 expression was inversely correlated with PPP3CC expression in glioma and there was a potential ZEB1 binding site in the potential PPP3CC promoter, it was necessary to verify whether ZEB1 transcriptionally regulated PPP3CC expression in glioma. ZEB1 was highly expressed in the selected glioma cell lines (Fig. 5A ). It was found that ZEB1 knockdown significantly up-regulated PPP3CC expression in mRNA and protein levels in U-118MG and SW1088 cell lines (Fig. 5B) . To confirm the direct association of ZEB1 with the PPP3CC promoter, ChIP assays were performed in the U-118MG and SW1088 cell lines and indicated that ZEB1 was bound to the PPP3CC promoter (Fig. 5C ). To determine whether ZEB1 could regulate PPP3CC promoter activity, the potential PPP3CC promoter was cloned into the pGL4 reporter plasmid. The experimental results indicated that luciferase activity driven by the potential PPP3CC promoter was lower in the U-118MG and SW1088 cell lines, compared with the control (Fig. 4D) . However, ZEB1 knockdown enhanced the luciferase activity driven by PPP3CC promoter in U-118MG and SW1088 cell lines (Fig. 5E ). These results implied that ZEB1 was able to directly bind to PPP3CC promoter to transcriptionally repress PPP3CC expression in glioma cells.
Discussion
The NF-κB signaling is a multi-component pathway and determines the expression of target genes involved in various biological processes. The dysregulation of NF-κB signaling at different levels, such as by mutations and epigenetic mechanisms, is involved in many human diseases, especially inflammation and cancer (11) . NF-κB signaling is usually activated in cancers, whereas the mechanisms of activation appear to be complex and vary in different cancer types (12) . The mechanisms of causing and maintaining the constitutive NF-κB activation in cancer cells are largely unclear. It has been reported that calcineurin (also called protein phosphatase 2B or PP2B) can either increase or inhibit NF-κB activity (13) . Prostate cancer tissue microarray data show that PPP3CC expressed is decreased and its decrease is associated with prostate cancer recurrence (14) . Here, our studies demonstrate that the PPP3CC decrease contributes to the constitutive NF-κB activation in glioma cells. PPP3CC decrease is also correlated with p-IκBα increase in glioma tissues. NF-κB pathway is involved in many biological events in cells, directly inhibiting it may leads to serious side effect on cells. however, the regulation network of NF-κB is quite complex, without this pathway, other pathway can regulate (15, 16) . So we think that NF-κB would not be inhibited completely. In the future, we aimed to develop intervention strategies targeting ZEB1/PPP3C to inhibit glioma development. The mechanisms of PPP3CC dysregulation in cancer are still unclear. As PPP3CC expression is transcriptionally repressed in gliomas, our study screened transcription factors regulating PPP3CC expression. The bioinformatics prediction and experimental validation indicates that the transcriptional repressor ZEB1 binds to PPP3CC promoter and represses its expression in glioma cells. ZEB1, as a critical EMT-inducer, promotes cancer cells invasion and metastasis (17) . ZEB1 has been found to be highly expressed in some cancer types and correlated with poor prognosis (18) . ZEB1 induces EMT process via transcriptionally regulating the expression of cell adhesion molecules and polarity-associated genes, resulting into metastasis, therapy resistance and poor clinical outcome (19, 20) . ZEB1 not only controls EMT-associated processes like cell mobility but also stemness and survival (21) . In glioma, it has been reported that ZEB1 could be induced by the tumor micro-environmental manner and then promotes invasion (22) . Siebzehnrubl et al. also reported the critical role of ZEB1 in glioma initiation, invasion, therapy resistance and outcomes (23) . Our study demonstrated that ZEB1 overexpression in glioma led to PPP3CC down-regulation, suggesting a novel mechanism for the role of ZEB1 in glioma progression.
Taken together, the data from our study demonstrate that PPP3CC expression is down-regulated in glioma and its decrease confers NF-κB activation. PPP3CC inhibits cells invasion and growth. The elucidation of the ZEB1-PPP3CC axis provides novel insights into the molecular mechanisms underlying the progression of glioma and provides a rationale for the development of clinical anticancer intervention strategies based on targeting the ZEB1-PPP3CC axis.
